Peroxisome proliferator-activated receptor-gamma 34C>G polymorphism and colorectal cancer risk: a meta-analysis.
OBJECTIVE
To investigate the association between peroxisome proliferator-activated receptor-gamma (PPAR-gamma) gene polymorphism 34 C>G and colorectal cancer (CRC), a meta-analysis review was performed in this report.


METHODS
A systematic literature search and selection of eligible relevant studies were carried out. Nine independent studies with a total number of 4533 cases and 6483 controls were included in the meta-analysis on the association between polymorphism 34 C>G and CRC.


RESULTS
There was no evidence for the association between PPAR-gamma 34 C>G and CRC if all of the subjects in the nine studies were included. However, CG + GG showed a marginally significant difference from CC (OR = 0.84, 95% CI: 0.69-1.01, P = 0.07) in random-effect model. Stratified meta-analysis indicated that PPAR-gamma 34 C>G was associated with colon cancer (OR = 0.8, 95% CI: 0.65-0.99, P = 0.04) in random-effect model, and the G allele decreased colon cancer risk. No significant association was observed between PPAR-gamma 34 C>G and rectal cancer.


CONCLUSIONS
PPAR-gamma 34 C>G is associated with colon cancer risk, but not associated with CRC and rectal cancer risk.
Lu
Yong-Liang
YL
Department of Surgery, Huzhou Teachers College School of Medicine, Huzhou 313000, Zhejiang Province, China.
Li
Gai-Ling
GL
Huang
Hui-Lian
HL
Zhong
Jing
J
Dai
Li-Cheng
LC
D000483:Alleles; D016022:Case-Control Studies; D015179:Colorectal Neoplasms / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D006801:Humans; D008957:Models, Genetic; D047495:PPAR gamma / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors
D047495:PPAR gamma